AUTHOR=Donadeu Laura , Gomez-Olles Susana , Casanova Franc , Torija Alba , Lopez-Meseguer Manuel , Boada-Pérez Meritxell , Kervella Delphine , Crespo Elena , Carrera-Muñoz Claudia , Campos-Varela Isabel , Castells Lluís , Cortese Maria F. , Esperalba Juliana , Fernández-Naval Candela , Quintero Jesús , Muñoz Marina , Agüero Fernando , Gonzalez-Costello José , Lladó Laura , Favà Alexandre , Cañas Laura , del Mar de la Hoz-Caballero María , Meneghini Maria , Torres Irina B. , Juvé Mariona , Hafkamp FMJ , Vila Marta , Robles Alba G. , Buzón Maria José , Toapanta Nestor , Zúñiga José Miguel , Monforte Víctor , Saez-Giménez Berta , Len Oscar , Arcos Ibai Los , Miret Enric , Ariceta Gema , Pardo Emma , Martínez Xavier , Moreso Francesc , Bestard Oriol TITLE=Role of SARS-CoV-2-specific memory B cells promoting immune protection after booster vaccination in solid organ transplantation JOURNAL=Frontiers in Immunology VOLUME=15 YEAR=2024 URL=https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2024.1463769 DOI=10.3389/fimmu.2024.1463769 ISSN=1664-3224 ABSTRACT=Introduction

Solid organ transplant (SOT) recipients display weak seroconversion and neutralizing antibody (NAb) responses after severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination and remain at risk of severe coronavirus disease 2019 (COVID-19). While B-cell memory is the hallmark of serological immunity, its role in driving successful vaccine responses and providing immune protection in SOT patients remains unclear.

Methods

We investigated the function and interplay of SARS-CoV-2-specific memory B cells (mBc), different cytokineproducing T cells, and cross-reactive NAb in driving seroconversion and protection against COVID-19 in two cohorts. First, we studied a large cohort of 148 SOT recipients and 32 immunocompetent individuals who underwent several vaccinations. Subsequently, we assessed 25 SOT patients participating in a randomized controlled trial to compare two different immunosuppressive strategies for allowing successful seroconversion and memory-cell responses after booster vaccination.

Results

We corroborate previous findings that B- and T-cell memory responses are weaker and more delayed in SOT patients than in immunocompetent (IC) individuals; however, within the SOT cohort, we found that these responses are relatively stronger and more robust in patients not receiving mycophenolate mofetil (MMF)-based therapies. Anti- spike IgG titers strongly correlated with RBD-specific IgG-producing mBc, with both displaying broad viral cross reactivity. Prebooster SARS-CoV-2-specific mBc and IL-2- producing T cells accurately predicted Nab seroconversion (AUC, 0.828) and protection against severe COVID-19. While switching unresponsive SOT patients from calcineurin inhibitors (CNI)/MMF to a low-exposure CNI/mTOR-i regimen favored wider SARS-CoV-2-specific immune responses after a fourth booster vaccination, preformed RBD-specific mBc predicted NAb seroconversion.

Discussion

Our study adds new insights into the pathobiology of immune memory and highlights the pivotal role of SARS-CoV-2-specific mBc in promoting immune protection inSOT patients.